Here's Why Viking Therapeutics Stock Surged Higher in June
Key takeaways
- VKTX LLY NOVO-B.CO NVDA Viking Therapeutics (NASDAQ: VKTX) stock rose by 19.2% in June, according to data from S&P Global Market Intelligence.
- Speaking of GLP-1/GIP class drugs, Viking's lead drug candidate, VK2735, is a GLP-1/GIP agonist.
- In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia.
VKTX LLY NOVO-B.CO NVDA Viking Therapeutics (NASDAQ: VKTX) stock rose by 19.2% in June, according to data from S&P Global Market Intelligence. The move comes as optimism rises over the company's pipeline development program, notably in weight-loss drugs, and the initiation of a Phase 1 study in a new class of weight-loss drugs that offers a different mechanism from the current GLP-1/GIP class.
Speaking of GLP-1/GIP class drugs, Viking's lead drug candidate, VK2735, is a GLP-1/GIP agonist. It's part of a crowded field that includes blockbuster weight loss drugs from Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO).
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »